C - Chemistry – Metallurgy – 07 – C
Patent
C - Chemistry, Metallurgy
07
C
C07C 279/14 (2006.01) A61K 31/167 (2006.01) A61K 31/435 (2006.01) A61P 3/10 (2006.01) C07C 277/08 (2006.01) C07D 213/75 (2006.01)
Patent
CA 2359454
The invention relates to pharmaceutical composition comprising as active principle a compound of general formula (I) (see formula I) in which: R1 is selected from one of the following groups: - H; and -(C1-C20)alkyl substituted or unsubstituted by one or more of the following groups: amino, hydroxyl, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, trifluoromethyl; R2 is selected from -(C3-C8)cycloalkyl substituted or unsubstituted by one or more of the following groups: amino, hydroxyl, (C1-C5) alkyl, (C1-C5) alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, trifluoromethyl; -(C6-C14)aryl substituted or unsubstituted by one or more of the following groups: amino, hydroxyl, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, trifluoromethyl, cyano; and heteroaryl selected from pyridyl, pyrimidinyl, furyl, pyrrolyl, thienyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzothienyl, indolyl, benzofuryl and imidazolyl, optionally substituted by one or more of the following groups: amino, hydroxyl, halogen, (C1-C5) alkyl, (C1-C5) alkoxy, (C1-C5) alkylthio, (C1-C5) alkylamino, trifluoromethyl, cyano; a nitrogen atom can additionally be substituted by a(C6-C14) aryl, (C6-C14) acyl or (C1-C5) alkyl group; R3 is selected from - H; - (C3-C8)cycloalkyl substituted or unsubstituted by one or more of the following groups: amino, hydroxyl, (C1-C5) alkyl, (C1-C5) alkoxy, (C1-C5) alkylthio, (C1-C5) alkylamino, trifluoromethyl; - (C3-C8)heterocycloalkyl containing one or more heteroatoms selected from N, O and S and substituted or unsubstituted by one or more of the following groups: amino, hydroxyl, (C1-C5) alkyl, (C1-C5) alkoxy, (C1-C5) alkylthio, (C1-C5) alkylamino, trifluoromethyl; a nitrogen atom can additionally be substituted by a (C6-C14)aryl, (C6-C14) acyl or (C1-C5) alkyl group; -(C6-C14) aryl substituted or unsubstituted by one or more of the following groups: amino, hydroxyl, halogen, (C1-C5) alkyl, (C1-C5) alkoxy, (C1-C5) alkylthio, (C1-C5) alkylamino, trifluoromethyl, cyano; -(C1-C13) heteroaryl containing one or more heteroatoms selected from N, O and S and substituted or unsubstituted by one or more of the following groups: amino, hydroxyl, halogen, (C1-C5) alkyl, (C1-C5) alkoxy, (C1-C5) alkylthio, (C1-C5) alkylamino, trifluoromethyl, cyano; a nitrogen atom can additionally be substituted by a(C6-C14) aryl, (C6-C14) acyl or (C1-C5) alkyl group; and - (C6-C14) aryl- (C1-C5) alkyl substituted or unsubstituted by one or more of the following groups: amino, hydroxyl, halogen, (C1-C5) alkyl, (C1-C5) alkoxy, (C1-C5) alkylthio, (C1-C5) alkylamino, trifluoromethyl, cyano; and A is selected from the groups: -CH2-, -CH2-CH2-, and -CHR4-, R4 being selected from: -(C1-C20)alkyl substituted or unsubstituted by one or more of the following groups: amino, hydroxyl, (C1-C5) alkyl, (C1-C5) alkoxy, (C1-C5) alkylthio, (C1-C5) alkylamino, trifluoromethyl; - (C3-C8)cycloalkyl substituted or unsubstituted by one or more of the following groups: amino, hydroxyl, (C1-C5) alkyl, (C1-C5) alkoxy, (C1-C5) alkylthio, (C1-C5) alkylamino, trifluoromethyl; and -(C3-C8)heterocycloalkyl containing one or more heteroatoms selected from N, O and S and substituted or unsubstituted by one or more of the following groups: amino, hydroxyl, (C1-C5) alkyl, (C1-C5) alkoxy, (C1-C5) alkylthio, (C1-C5) alkylamino, trifluoromethyl; a nitrogen atom can additionally be substituted by a(C6-C14) aryl, (C6-C14) acyl or (C1-C5) alkyl group; or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient or vehicle. These compositions can be used in the treatment of pathologies associated with insulin resistance.
Cette invention concerne des compositions pharmaceutiques renfermant comme principe actif une composition pharmaceutique représenté par la formule générale (I) dans laquelle R1, R2, R3 et A sont conformes à la définition donnée dans la revendication 1. Ces compositions peuvent s'utiliser pour le traitement de pathologies associées au syndrome de résistance à l'insuline.
Cravo Daniel
Doare Liliane
Kergoat Micheline
Mesangeau Didier
Moinet Gerard
Fetherstonhaugh & Co.
Merck Patent Gesellschaft Mit Beschraenkter Haftung
LandOfFree
((aminoiminomethyl) amino) alkanecarboxamides and their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ((aminoiminomethyl) amino) alkanecarboxamides and their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ((aminoiminomethyl) amino) alkanecarboxamides and their... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1911337